Phase
Condition
White Cell Disorders
Leukemia
Myelodysplastic Syndromes (Mds)
Treatment
Palliative Care Visits
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Ability to provide informed consent
Stated willingness to comply with all study procedures and availability for theduration of the study
Any of the following:
Patients with a new diagnosis of AML, ALL, high risk myelodysplastic syndrome (MDS), or high risk chronic myelomonocytic leukemia (CMML) who are age 65 andolder.OR
Patients with relapsed AML, ALL, high risk MDS or high risk CMML, ages 18 andolder.OR
Patients with refractory AML, ALL, high risk MDS or high risk CMML, ages 18 andolder.
Refractory AML/ALL will be defined as persistent leukemia despite two or more cycles of induction chemotherapy.
Refractory MDS will be defined according to the 2006 IWG response criteria Refractory CMML will be based on the assessment of the treating investigator.
Exclusion
Exclusion Criteria:
- Participants must not have a diagnosis of Acute Promyelocytic Leukemia (APL)
Study Design
Study Description
Connect with a study center
University of Virginia
Charlottesville, Virginia 22903
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.